JP2023516010A - 遺伝子送達システム - Google Patents

遺伝子送達システム Download PDF

Info

Publication number
JP2023516010A
JP2023516010A JP2022551783A JP2022551783A JP2023516010A JP 2023516010 A JP2023516010 A JP 2023516010A JP 2022551783 A JP2022551783 A JP 2022551783A JP 2022551783 A JP2022551783 A JP 2022551783A JP 2023516010 A JP2023516010 A JP 2023516010A
Authority
JP
Japan
Prior art keywords
payload
nucleic acid
protein
bacterium
dna vaccine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022551783A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023516010A5 (cg-RX-API-DMAC10.html
Inventor
アレクサンダー グレイブス、ハーバート
ライタータ、シータル
シーヴァース、エリック
ラマシャンドラン、ウーメシュ
チャン、ケビン
トプシーイ、エレナ
ギル、ナヴィ
セイヤー、サリー
シャー、フェニル
スティーア、カテリーヌ
トーマス、ライアン
チェン、メイ
シヴァラマン、シャラニア
ルー、ルーシー
- ドゥッチ、ソフィー ユリスト
チューリン、オレグ
マッケンジー、ロイド
Original Assignee
シムビーボ コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シムビーボ コーポレイション filed Critical シムビーボ コーポレイション
Publication of JP2023516010A publication Critical patent/JP2023516010A/ja
Publication of JP2023516010A5 publication Critical patent/JP2023516010A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/101—Plasmid DNA for bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/20—Pseudochromosomes, minichrosomosomes
    • C12N2800/204—Pseudochromosomes, minichrosomosomes of bacterial origin, e.g. BAC

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2022551783A 2020-02-25 2021-02-25 遺伝子送達システム Pending JP2023516010A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202062981464P 2020-02-25 2020-02-25
US62/981,464 2020-02-25
US202063079841P 2020-09-17 2020-09-17
US63/079,841 2020-09-17
PCT/CA2021/050236 WO2021168577A1 (en) 2020-02-25 2021-02-25 Gene delivery system

Publications (2)

Publication Number Publication Date
JP2023516010A true JP2023516010A (ja) 2023-04-17
JP2023516010A5 JP2023516010A5 (cg-RX-API-DMAC10.html) 2024-03-05

Family

ID=77490538

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022551783A Pending JP2023516010A (ja) 2020-02-25 2021-02-25 遺伝子送達システム

Country Status (5)

Country Link
US (1) US20250242012A1 (cg-RX-API-DMAC10.html)
EP (1) EP4110401A4 (cg-RX-API-DMAC10.html)
JP (1) JP2023516010A (cg-RX-API-DMAC10.html)
CA (1) CA3168968A1 (cg-RX-API-DMAC10.html)
WO (1) WO2021168577A1 (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4117697A1 (en) * 2020-03-13 2023-01-18 PrecisionBiotics Group Limited Bifidobacterium longum
JP2024511941A (ja) * 2021-03-11 2024-03-18 テンザ、インク. 酵母における異種タンパク質の分泌を指示するための合成シグナルペプチド
CA3177045A1 (en) * 2021-03-15 2022-09-22 Beth Israel Deaconess Medical Center, Inc. Compositions and methods for treating coronavirus infection

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994006903A1 (en) * 1992-09-22 1994-03-31 Dnx Biotherapeutics, Inc. Delivery of proteins by intermembrane transfer for preaccommodation of xenogeneic organ transplants and other purposes
JP2003518929A (ja) * 1999-12-23 2003-06-17 ユニヴェルシテ・ドゥ・ジュネーブ 基底側部選別シグナル、およびその阻害物質
JP2008515808A (ja) * 2004-10-04 2008-05-15 トリニティ バイオシステムズ インコーポレーテッド 針不用の高分子送達のための方法及び組成物
JP2009533018A (ja) * 2006-02-28 2009-09-17 バクサート インコーポレーティッド キメラアデノウイルスベクター
JP2009537124A (ja) * 2006-05-17 2009-10-29 エフ.ホフマン−ラ ロシュ アーゲー ポリペプチド産生細胞
US20100269180A1 (en) * 2009-04-17 2010-10-21 Barbara Ranscht Methods, compositions and transgenic models related to the interaction of t-cadherin and adiponectin
WO2014168064A1 (ja) * 2013-04-10 2014-10-16 国立大学法人浜松医科大学 Lix1l高発現腫瘍細胞の増殖阻害方法、及び腫瘍細胞増殖抑制ペプチド
JP2017505637A (ja) * 2014-02-14 2017-02-23 シンヴィヴォ コーポレイション 核酸ベクターおよびその使用
WO2018123507A1 (ja) * 2016-12-26 2018-07-05 国立大学法人神戸大学 経口腫瘍ワクチンと免疫抑制阻害剤との併用によるがん治療

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170121291A (ko) * 2015-03-02 2017-11-01 신로직 인코포레이티드 감소된 창자 염증 및/또는 강화된 창자 점막 장벽으로부터 이익을 얻는 질병을 치료하기 위해 공학처리된 박테리아
US10695385B2 (en) * 2015-06-25 2020-06-30 National University Corporation Kobe University Oral cancer vaccine
AU2018301667A1 (en) * 2017-07-12 2020-02-06 Fundação D. Anna De Sommer Champalimaud E Dr. Carlos Montez Champalimaud Foundation Methods and systems for conditionally regulating gene expression

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994006903A1 (en) * 1992-09-22 1994-03-31 Dnx Biotherapeutics, Inc. Delivery of proteins by intermembrane transfer for preaccommodation of xenogeneic organ transplants and other purposes
JP2003518929A (ja) * 1999-12-23 2003-06-17 ユニヴェルシテ・ドゥ・ジュネーブ 基底側部選別シグナル、およびその阻害物質
JP2008515808A (ja) * 2004-10-04 2008-05-15 トリニティ バイオシステムズ インコーポレーテッド 針不用の高分子送達のための方法及び組成物
JP2009533018A (ja) * 2006-02-28 2009-09-17 バクサート インコーポレーティッド キメラアデノウイルスベクター
JP2009537124A (ja) * 2006-05-17 2009-10-29 エフ.ホフマン−ラ ロシュ アーゲー ポリペプチド産生細胞
US20100269180A1 (en) * 2009-04-17 2010-10-21 Barbara Ranscht Methods, compositions and transgenic models related to the interaction of t-cadherin and adiponectin
WO2014168064A1 (ja) * 2013-04-10 2014-10-16 国立大学法人浜松医科大学 Lix1l高発現腫瘍細胞の増殖阻害方法、及び腫瘍細胞増殖抑制ペプチド
JP2017505637A (ja) * 2014-02-14 2017-02-23 シンヴィヴォ コーポレイション 核酸ベクターおよびその使用
WO2018123507A1 (ja) * 2016-12-26 2018-07-05 国立大学法人神戸大学 経口腫瘍ワクチンと免疫抑制阻害剤との併用によるがん治療

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ARCH. VIROL., vol. 158, JPN6025009809, 2013, pages 1071 - 1077, ISSN: 0005546862 *
VACCINE, vol. 32, JPN6025009810, 2014, pages 3066 - 3074, ISSN: 0005546863 *

Also Published As

Publication number Publication date
WO2021168577A1 (en) 2021-09-02
US20250242012A1 (en) 2025-07-31
EP4110401A1 (en) 2023-01-04
EP4110401A4 (en) 2024-03-27
CA3168968A1 (en) 2021-09-02

Similar Documents

Publication Publication Date Title
US10954521B1 (en) Immunization and/or treatment of parasites and infectious agents by live bacteria
JP6728257B2 (ja) バイオフィルムの除去のための組成物および方法
US9421252B2 (en) Live bacterial vaccines resistant to carbon dioxide (CO2), acidic pH and/or osmolarity for viral infection prophylaxis or treatment
AU2024201593A1 (en) A genetically modified Lactobacillus and uses thereof
KR20190082850A (ko) 반복되는 암 돌연변이를 표적화하는 면역원 조성물 및 그것의 사용 방법
EP3402498A1 (en) Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells
Njongmeta et al. CD205 antigen targeting combined with dendritic cell recruitment factors and antigen-linked CD40L activation primes and expands significant antigen-specific antibody and CD4+ T cell responses following DNA vaccination of outbred animals
JP2016527199A5 (cg-RX-API-DMAC10.html)
US20250242012A1 (en) Gene delivery system
US20240091307A1 (en) Combination therapies of amuc_1100 and immune checkpoint modulators for use in treating cancers
Holzapfel et al. Escape of TLR5 recognition by Leptospira spp.: a rationale for atypical endoflagella
JP2023511282A (ja) シュウ酸塩が有害となる障害を治療するための遺伝子改変細菌
TW201833323A (zh) 重組李斯特菌屬疫苗菌株及在癌症免疫治療中使用該菌株之方法
CA3063419A1 (en) Live salmonella typhi vectors engineered to express heterologous outer membrane protein antigens and methods of use thereof
CA3238993A1 (en) Genetically modified microorganism and use thereof
Liang et al. Replenishing decoy extracellular vesicles inhibits phenotype remodeling of tissue-resident cells in inflammation-driven arthritis
JP2024511230A (ja) 浸潤し、かつ自律的に溶解するように設計された治療用タンパク質の細胞内送達およびその使用方法
JP2004525931A (ja) バクテリオファージによって仲介される免疫化方法
CN103025341B (zh) 胰岛素样生长因子1受体结合肽
CZ20023795A3 (cs) Izolace a charakterizace csa operonu (ETEC-CS24 PILI) a způsob jeho použití
JP2024529044A (ja) レプトスピラ病毒性調節タンパク質とその使用
Zhang et al. Bacterial ghosts engineered with lipidated antigens as an adjuvant-free vaccine for Chlamydia abortus
WO1994025598A2 (en) Methods and compositions for salmonella-based vaccines
CN110214028A (zh) 联合使用口服肿瘤疫苗和免疫抑制阻滞剂的癌症治疗
KR20200004774A (ko) 면역원성시스템 및 이를 포함한 동물 백신

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240226

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240226

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250311

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250902